Short Ragweed (AMBROSIA ARTEMISIIFOLIA)
Short Ragweed (AMBROSIA ARTEMISIIFOLIA) is one of 8,063 medications in the MedPlain dataset. Key details — Brand name: Short Ragweed; Generic name: AMBROSIA ARTEMISIIFOLIA; Drug class: Standardized Pollen Allergenic Extract [EPC].
| Brand name | Short Ragweed |
|---|---|
| Generic name | AMBROSIA ARTEMISIIFOLIA |
| Drug class | Standardized Pollen Allergenic Extract [EPC] |
| Manufacturer | Allermed Laboratories, Inc. |
| Used for | INDICATIONS Studies have shown that properly performed an interpreted skin tests with ragweed pollen extract are useful in the diagnosis of allergy to ragweed pollen 7, 8, 20, 21 . Immunotherapy with the appropriate dosage of short ragweed pollen extract is effective in reducing symptoms of hay fever and asthma resulting from exposure to short ragweed pollen (9, 10, 11), and it is believed to be effective with extract of giant ragweed, although carefully controlled studies are unavailable. However, clinical observations and known cross reactivity between short and giant ragweed pollens have led to the practice of using a mixture of the two species for skin testing and treatment 22, 23, 24, 2 |
| Dosage | DOSAGE AND ADMINISTRATION DIAGNOSIS. If the extract supplied in this package is concentrated product (w/v 1:20), it should not be used for intradermal testing. Concentrated extract may be used for scratch or prick testing providing the patient is not exposed to high levels of ragweed pollen and experiencing pronounced symptoms of hay fever or asthma at the time of testing. Extract for intradermal testing must be diluted to a strength of 0.25 units of antigen E per ml 7 . Skin tests should not be |
| Warnings | WARNINGS Physicians who elect to administer ragweed pollen extract should be familiar with the clinical use of allergenic extracts and have the necessary emergency equipment and medication available to treat systemic allergic reactions. The injection of ragweed pollen extract may cause severe local and/ or systemic anaphylactic reactions in some individuals. To minimize this potential hazard, the relative sensitivity of the patient must be assessed from the allergic history and from clinical obs |
| Active ingredient(s) | AMBROSIA ARTEMISIIFOLIA POLLEN |
| Route | CUTANEOUS |
| Official label | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1482f8a2-c2c0-45a1-8e90-b427227f0b28 |